1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Gelesis Holdings, Inc.

Gelesis Holdings, Inc.

GLSHQ
Gelesis Holdings, Inc.US flagOther OTC
0.00
USD
- -
- -
7,334.00Market Cap
Gelesis Holdings, Inc.
GLSHQ
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2021
2022
TTM
FRC
0.15
0.37
0.17
Revenue per Share
-1.3
-0.81
-0.71
Basic EPS, GAAP
-1.04
-1.24
-0.69
Free Cash Flow per Basic Share
- -
- -
- -
Dividend per Share
-3.68
-4.59
-4.59
Book Value per Share
-4.62
-0.37
-0.42
Tangible Book Value per Share
72
70
73
Basic Weighted Avg Shares
11
26
12
Sales/Revenue/Turnover
-759.7
-472.72
-546.48
Operating Margin (%)
4
5
8
Depreciation Expense
-94
-57
-52
Net Income, GAAP
- -
- -
- -
Effective Tax Rate (%)
-837.93
-221.71
-425.58
Profit Margin (%)
-3
-27
-26
Working Capital
37
26
28
LT Debt
-318
-12
-19
Total Equity
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
Return on Capital (%)
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'22
Mar'23
Jun'23
ST Debt
36
34
34
LT Borrowings
25
26
27
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
73
73
73
Market Capitalization
20
12
3

Working Capital

FRC

•

in mil. unless spec.
Dec'22
Mar'23
Jun'23
Total Current Assets
23
25
25
Cash, Cash Equivalents & STI
7
3
8
Accounts Receivable, Net
1
1
1
Inventories
7
6
6
Total Current Liabilities
51
49
50
Payables & Accruals
14
15
16
ST Debt
36
34
34
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-96.08%
Free Cash Flow
- -
- -
15.48%
Net Income, GAAP
- -
- -
-39.05%
Sales/Revenue/Turnover
- -
- -
130.37%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
11
2022
8
9
7
3
26
2023
2
1
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
-1.3
2022
-0.09
-0.17
-0.2
- -
-0.81
2023
-0.07
-0.1
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
Similar Companies
Ultragenyx Pharmaceutical Inc. (RARE)
Genfit S.A. (GNFT.PA)
Synlogic, Inc. (SYBX)
PharmaCyte Biotech, Inc. (PMCB)
Graybug Vision, Inc. (GRAY)
Compugen Ltd. (CGEN.TA)
Business
Gelesis Holdings, Inc. was a biotherapeutics firm that engaged in developing innovative biomimicry solutions for conditions such as excess weight and various gastrointestinal chronic illnesses. The company's flagship offering was PLENITY, an orally administered, non-systemic and non-stimulant preparation designed to aid in weight management. Additionally, Gelesis was actively progressing candidates like GS200 for addressing weight loss in individuals with prediabetes and type 2 diabetes, alongside GS500 for functional constipation. Early-stage investigations also included GS300, aimed at non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Founded in 2006, the company maintained its headquarters in Boston, Massachusetts. However, Gelesis Holdings, Inc., along with its affiliates, initiated a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware on October 30, 2023, ceasing all operations at that time. Subsequently, a Chapter 7 trustee was appointed, and substantially all of the company's assets, including its intellectual property, were sold in July 2024.